A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

NCT06382142 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

418

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-Negative Breast Cancer

Interventions

DRUG: BL-B01D1
DRUG: Eribulin
DRUG: Vinorelbine
DRUG: Gemcitabine
DRUG: Capecitabine

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]